4/A: Cumberland Pharmaceuticals Director Corrects Stock Acquisition Report
SEC Filing (Form 4/A Amendment)
Martin S. Brown Jr., a director at Cumberland Pharmaceuticals, amended a previous SEC filing to correct the number of shares acquired on March 25, 2024.
Summary
- Martin S. Brown Jr., a director of Cumberland Pharmaceuticals, filed an amendment to a previous Form 4.
- The amendment corrects the number of shares acquired on March 25, 2024.
- The original filing reported 1,000 shares acquired, but the correct number is 2,500 shares.
- This reflects an increase of 1,500 shares from the originally reported amount.
- Following the transaction, Brown directly owns 7,500 shares of Common Stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing correcting a previous error. It doesn't contain any information that would significantly impact investor sentiment positively or negatively.
Industry Context
This filing is a routine disclosure related to insider trading activity, which is a common occurrence in publicly traded companies. It provides transparency to investors regarding the transactions of company insiders.
Stakeholder Impact
- The correction of the filing ensures accurate information is available to shareholders and the public.
Key Dates
| Date | Description |
|---|---|
| 03/25/2024 | Date of the stock acquisition. |
| 03/26/2024 | Date of the original Form 4 filing. |
| 01/30/2025 | Date of signature on the amended form. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.